NC
AVIR icon

NinePointTwo Capital’s Atea Pharmaceuticals AVIR Stock Holding History

NinePointTwo Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,844
Closed -$132K – 227
2021
Q4 		$132K Buy
+14,844
New +$231K 0.04% 174

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NinePointTwo Capital's AVIR Position: Q1 2022 in Review

NinePointTwo Capital sold out of Atea Pharmaceuticals (AVIR) in Q1 2022, closing a stake of 14,844 shares — an estimated $132K sold.

NinePointTwo Capital first reported a position in AVIR in Q4 2021 and held it in 1 quarter. The position peaked at $132K in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2022.

  • NinePointTwo Capital reported no remaining Atea Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • NinePointTwo Capital sold 14,844 Atea Pharmaceuticals shares in Q1 2022, an estimated $132K.
  • NinePointTwo Capital first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • NinePointTwo Capital's Atea Pharmaceuticals position peaked at $132K in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2022.

Based on NinePointTwo Capital's 13F filing for Q1 2022, filed 16 May 2022.